MENU
LFSC
ETF ticker: NASDAQ
PRICE
CHANGE
NET ASSETS

LFSC stock forecast, quote, news & analysis

The investment seeks long-term capital appreciation... Show more

Category: #Health
LFSC
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for LFSC with price predictions
Jul 31, 2026

LFSC in +0.65% Uptrend, advancing for three consecutive days on July 28, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where LFSC advanced for three days, in of 102 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 19 cases where LFSC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 89 cases where LFSC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for LFSC moved out of overbought territory on July 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 19 similar instances where the indicator moved out of overbought territory. In of the 19 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on July 31, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LFSC as a result. In of 28 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for LFSC turned negative on July 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 15 similar instances when the indicator turned negative. In of the 15 cases the stock turned lower in the days that followed. This puts the odds of success at .

LFSC broke above its upper Bollinger Band on July 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Guardant Health (NASDAQ:GH), Sarepta Therapeutics (NASDAQ:SRPT).

Industry description

The investment seeks long-term capital appreciation. The fund is an actively managed exchange-traded fund (“ETF”) and invests primarily in equity securities of life science companies selected by Emerald Mutual Fund Advisers Trust, the fund’s investment sub-adviser, under the supervision of the adviser. Under normal market conditions, the fund invests at least 80% of its net assets in equity securities issued by life science companies demonstrating innovation.

Market Cap

The average market capitalization across the F/m Emerald Life Sciences Innovation ETF ETF is 6.35B. The market cap for tickers in the group ranges from 476.98M to 21.98B. UTHR holds the highest valuation in this group at 21.98B. The lowest valued company is OFIX at 476.98M.

High and low price notable news

The average weekly price growth across all stocks in the F/m Emerald Life Sciences Innovation ETF ETF was 1%. For the same ETF, the average monthly price growth was 0%, and the average quarterly price growth was 28%. ITGR experienced the highest price growth at 23%, while NVCR experienced the biggest fall at -16%.

Volume

The average weekly volume growth across all stocks in the F/m Emerald Life Sciences Innovation ETF ETF was 25%. For the same stocks of the ETF, the average monthly volume growth was -24% and the average quarterly volume growth was -36%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 71
P/E Growth Rating: 74
Price Growth Rating: 51
SMR Rating: 83
Profit Risk Rating: 79
Seasonality Score: 0 (-100 ... +100)
View a ticker or compare two or three
LFSC
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Details
LFSC in +0.65% Uptrend, advancing for three consecutive days on July 28, 2026